In a real-world setting, the administration of oral semaglutide leads to a significant reduction in the urinary ...

Among patients receiving semaglutide for obesity management, the risk for muscle loss may be higher in older adults and women ...

People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to ...

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

Ozempic, a drug known for its physical health benefits, is now gaining recognition for its effectiveness in treating ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and ...

Boosting protein intake helped semaglutide users to protect against some of this lean muscle loss, though. At month 3 of ...